TrojanBio
TrojanBio develops antibody therapies that stimulate antiviral immune responses to target and kill cancer cells. The company engineers “Trojan” antibodies that integrate viral peptides into antibody constructs to activate cytotoxic immune mechanisms against tumor tissues. TrojanBio operates as a biopharmaceutical/biotech developer focused on therapeutic antibodies and immuno-oncology, advancing candidates toward clinical use. Its pipeline targets oncology and antiviral-related indications, with end users including patients, healthcare providers, and potential pharmaceutical partners.
TrojanBio
TrojanBio develops antibody therapies that stimulate antiviral immune responses to target and kill cancer cells. The company engineers “Trojan” antibodies that integrate viral peptides into antibody constructs to activate cytotoxic immune mechanisms against tumor tissues. TrojanBio operates as a biopharmaceutical/biotech developer focused on therapeutic antibodies and immuno-oncology, advancing candidates toward clinical use. Its pipeline targets oncology and antiviral-related indications, with end users including patients, healthcare providers, and potential pharmaceutical partners.